Arbutus Biopharma Cp (ABUS)

$3.06 -0.08 (-2.55%)
Market Cap 592.57M
Revenue (ttm) 18.14M
Net Income (ttm) -72.85M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 649,900
Avg Vol 936,122
Day's Range N/A - N/A
Shares Out 188.72M
Stochastic %K 2%
Beta 1.98
Analysts Strong Sell
Price Target $4.50

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the poten...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 469 0914
Address:
701 Veterans Circle, Warminster, United States
Reasonableturd
Reasonableturd Oct. 4 at 5:55 PM
$ABUS How much value is attributed to HBV assets Vs the 33% share of the lawsuits?
1 · Reply
BRTO
BRTO Oct. 4 at 5:46 PM
$ABUS is a $1B company @ ~ $5.20 / share. Just making the math easy for all you buy out speculators. O-H
0 · Reply
DocPharm
DocPharm Oct. 4 at 4:08 PM
$BNTX bought the other 💎 $CVAC for mRNA patents (waiting for conversion) Will they or $PFE buy the gem $ABUS / ROIV/ Genevant for the LNP patents ? Very plausible
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 4 at 2:16 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ABUS Current Share Price: $4.38 Contracts: $ABUS January 15, 2027 $4 Calls Scale in: $1.74- $2.13 Scale out: $2.71-$3.48 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
EdDwg
EdDwg Oct. 4 at 1:39 PM
$ABUS Finally realizing the genius foresight of staggering the lawsuits against Moderna first with Pfizer later. Moderna has a weaker financial situation. When we win this lawsuit it will BK them and there will be a fire sale for their pipeline. Just another cautionary tale of flying too close to the sun. Pfizer is a legacy company with deep coffers that can potentially ante up treble damages. They should settle. They should settle before Moderna trial. They have too much to lose. Also, Acuitas provides no cover for Moderna. Pfizer had that going for them. However, an imminent court victory against Moderna weakens the Acuitas indemnification angle. Like playing chess. Check.............. Check...... Check...
1 · Reply
bowfin2
bowfin2 Oct. 4 at 2:06 AM
$ABUS If HBV is part of a deal / settlement with PFE, they should not take too much time? HBV has to be developed for the market.
2 · Reply
DocPharm
DocPharm Oct. 3 at 9:22 PM
$ROIV wonder if they are taking Genevant public Weird for a prospectus for 2022 to be lumped in $ABUS
3 · Reply
Thepatientone
Thepatientone Oct. 3 at 8:17 PM
$ABUS As i have said before 12-15% royalty rate plus milestones, interest and legal and treble damages to choke them completely.
2 · Reply
jrothman22
jrothman22 Oct. 3 at 7:37 PM
$ABUS
3 · Reply
Grtgooglymoogly
Grtgooglymoogly Oct. 3 at 7:06 PM
$ABUS Still feels like a low volume "raid" for shares. Hope for another high volume recovery into the close. (And news on Monday)
0 · Reply
Latest News on ABUS
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 7:30 AM EDT - 2 months ago

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Jun 25, 2025, 7:30 AM EDT - 3 months ago

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 7:30 AM EDT - 5 months ago

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

May 7, 2025, 2:01 AM EDT - 5 months ago

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Apr 23, 2025, 2:01 AM EDT - 5 months ago

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Mar 27, 2025, 7:56 AM EDT - 6 months ago

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Mar 27, 2025, 7:30 AM EDT - 6 months ago

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Mar 3, 2025, 9:15 AM EST - 7 months ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ROIV

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Feb 25, 2025, 7:00 AM EST - 7 months ago

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

Jan 30, 2025, 3:40 PM EST - 8 months ago

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

BUR CDZI

Arbutus Provides 2025 Corporate and Financial Update

Jan 13, 2025, 7:30 AM EST - 9 months ago

Arbutus Provides 2025 Corporate and Financial Update

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Jan 7, 2025, 7:56 AM EST - 9 months ago

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Dec 3, 2024, 8:00 AM EST - 10 months ago

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Nov 26, 2024, 7:30 AM EST - 11 months ago

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Nov 15, 2024, 11:02 AM EST - 11 months ago

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Arbutus to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 11 months ago

Arbutus to Present at Jefferies London Healthcare Conference

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 2:52 PM EST - 11 months ago

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Oct 15, 2024, 8:16 AM EDT - 1 year ago

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Arbutus to Participate in Two Upcoming Investor Conferences

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 2:00 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Jul 5, 2024, 5:29 AM EDT - 1 year ago

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Jun 6, 2024, 11:15 AM EDT - 1 year ago

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Jun 5, 2024, 2:30 AM EDT - 1 year ago

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Arbutus Distributors Ltd. News Release

Jun 3, 2024, 9:50 AM EDT - 1 year ago

Arbutus Distributors Ltd. News Release

Arbutus to Participate in Jefferies Global Healthcare Conference

May 29, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Jefferies Global Healthcare Conference

Arbutus to Present Imdusiran Data at EASL Congress 2024

May 22, 2024, 2:00 AM EDT - 1 year ago

Arbutus to Present Imdusiran Data at EASL Congress 2024

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

May 17, 2024, 9:00 AM EDT - 1 year ago

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

May 2, 2024, 1:15 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

May 2, 2024, 7:25 AM EDT - 1 year ago

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Apr 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Apr 4, 2024, 8:30 AM EDT - 1 year ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 1:05 PM EST - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 7:30 AM EST - 1 year ago

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Feb 15, 2024, 7:30 AM EST - 1 year ago

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Jan 8, 2024, 7:30 AM EST - 1 year ago

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Nov 9, 2023, 4:01 PM EST - 2 years ago

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 11:06 AM EST - 2 years ago

Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:30 AM EST - 2 years ago

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Nov 7, 2023, 7:15 AM EST - 2 years ago

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Oct 24, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

Oct 18, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Oct 11, 2023, 8:05 AM EDT - 2 years ago

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Sep 11, 2023, 4:15 PM EDT - 2 years ago

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update

Jul 20, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

Jul 12, 2023, 7:30 AM EDT - 2 years ago

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

Reasonableturd
Reasonableturd Oct. 4 at 5:55 PM
$ABUS How much value is attributed to HBV assets Vs the 33% share of the lawsuits?
1 · Reply
BRTO
BRTO Oct. 4 at 5:46 PM
$ABUS is a $1B company @ ~ $5.20 / share. Just making the math easy for all you buy out speculators. O-H
0 · Reply
DocPharm
DocPharm Oct. 4 at 4:08 PM
$BNTX bought the other 💎 $CVAC for mRNA patents (waiting for conversion) Will they or $PFE buy the gem $ABUS / ROIV/ Genevant for the LNP patents ? Very plausible
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 4 at 2:16 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ABUS Current Share Price: $4.38 Contracts: $ABUS January 15, 2027 $4 Calls Scale in: $1.74- $2.13 Scale out: $2.71-$3.48 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
EdDwg
EdDwg Oct. 4 at 1:39 PM
$ABUS Finally realizing the genius foresight of staggering the lawsuits against Moderna first with Pfizer later. Moderna has a weaker financial situation. When we win this lawsuit it will BK them and there will be a fire sale for their pipeline. Just another cautionary tale of flying too close to the sun. Pfizer is a legacy company with deep coffers that can potentially ante up treble damages. They should settle. They should settle before Moderna trial. They have too much to lose. Also, Acuitas provides no cover for Moderna. Pfizer had that going for them. However, an imminent court victory against Moderna weakens the Acuitas indemnification angle. Like playing chess. Check.............. Check...... Check...
1 · Reply
bowfin2
bowfin2 Oct. 4 at 2:06 AM
$ABUS If HBV is part of a deal / settlement with PFE, they should not take too much time? HBV has to be developed for the market.
2 · Reply
DocPharm
DocPharm Oct. 3 at 9:22 PM
$ROIV wonder if they are taking Genevant public Weird for a prospectus for 2022 to be lumped in $ABUS
3 · Reply
Thepatientone
Thepatientone Oct. 3 at 8:17 PM
$ABUS As i have said before 12-15% royalty rate plus milestones, interest and legal and treble damages to choke them completely.
2 · Reply
jrothman22
jrothman22 Oct. 3 at 7:37 PM
$ABUS
3 · Reply
Grtgooglymoogly
Grtgooglymoogly Oct. 3 at 7:06 PM
$ABUS Still feels like a low volume "raid" for shares. Hope for another high volume recovery into the close. (And news on Monday)
0 · Reply
Alfalcon
Alfalcon Oct. 3 at 6:34 PM
$ABUS Added
0 · Reply
Shortsales
Shortsales Oct. 3 at 6:25 PM
$ABUS
3 · Reply
DocPharm
DocPharm Oct. 3 at 5:58 PM
$ABUS but will it go for 3.88?
2 · Reply
DocPharm
DocPharm Oct. 3 at 5:55 PM
$ABUS added
0 · Reply
Thalassophile
Thalassophile Oct. 3 at 5:06 PM
$ABUS https://youtu.be/JM3fodiK9rY?si=KvG1oYDGO6fz_t3S
0 · Reply
Shortsales
Shortsales Oct. 3 at 4:26 PM
$ABUS - It’s criminal 🤣😂🤣 SEC ????
3 · Reply
DocPharm
DocPharm Oct. 3 at 12:54 PM
$RGTI keep on chugga luggin Thanks Kramer - $ABUS will be next ‘Spec of the Year’
1 · Reply
Heavey
Heavey Oct. 3 at 10:12 AM
$ABUS tutes own 137m of a public float of 149m. Only a matter of time.
1 · Reply
DDRPOWER
DDRPOWER Oct. 3 at 12:22 AM
$ABUS They’re trying to shake people out with these meaningless drops. Question is: how many shares do they want!?
0 · Reply
J_Wayne
J_Wayne Oct. 2 at 11:34 PM
$ABUS needs to bounce off this lower trend-line tomorrow…
0 · Reply
J_Wayne
J_Wayne Oct. 2 at 8:41 PM
$ABUS knock it down, swoop it up. A few ¢ /share on a few million shares isn’t a bad day 😂
0 · Reply
MyBrokenBus
MyBrokenBus Oct. 2 at 7:23 PM
$ABUS ROIV continuing up, general market holding, XBI up, RSI here finally cooled... this low share walk down ain't fooling anybody, just get this bus on its rightful path already.
1 · Reply